OTC:PHRRF PharmaTher (PHRRF) Stock Price, News & Analysis → Has Trump Finally Gone Too Far? (From Insiders Exposed) (Ad) Free PHRRF Stock Alerts $0.16 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.16▼$0.1850-Day Range$0.15▼$0.3252-Week Range$0.06▼$0.32Volume145,431 shsAverage Volume492,413 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get PharmaTher alerts: Email Address Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. About PharmaTherPharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company's product pipeline includes KETARX, a hydrochloride injection for the treatment of Parkinson's disease, Amyotrophic Lateral Sclerosis, complex regional pain and Rett syndrome, and anesthesia and procedural sedation, as well as Ischemia reperfusion injury. It also develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX On-body pump for the maintenance of general anesthesia for diagnostic and surgical procedures. In addition, the company offers PHARMAPATCH, a microneedle patch technology solution, which includes hydrogel-forming and gelatin methacryloyl delivery system for the treatment of psychedelics and infectious diseases. Further, it has license agreement with BioRAE, Inc. for the development and commercialization of a novel biocompatible and biodegradable gelatin methacryloyl microneedle; and the University of Kansas to develop and commercialize the intellectual property of ketamine to treat ALS. The company also holds a patent and know-how license agreement with The Queen's University of Belfast to develop and commercialize hydrogel-forming microneedle patch delivery technology; and a license agreement with Gesval SA, as well as valuation and exclusive option agreement with Case Western Reserve University for development and commercialization for the intellectual property of ketamine for the treatment of Rett syndrome. PharmaTher Holdings Ltd. was incorporated in 2019 and is headquartered in Toronto, Canada.Read More PHRRF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHRRF Stock News HeadlinesMay 17 at 6:33 PM | stockhouse.comPharmaTher's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated CepharanthineMay 15 at 10:40 AM | finance.yahoo.comPharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated CepharanthineMay 11, 2024 | finanznachrichten.dePharmaTher Holdings Ltd.: PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for KetamineMay 10, 2024 | globenewswire.comPharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for KetamineMay 1, 2024 | finance.yahoo.comPharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated CepharanthineMay 1, 2024 | globenewswire.comPharmaTher's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated CepharanthineApril 18, 2024 | globenewswire.comPharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for KetamineApril 16, 2024 | globenewswire.comPharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for KetamineFebruary 23, 2024 | benzinga.comPharmaTher Holdings Stock (OTC:PHRRF), Short Interest ReportFebruary 21, 2024 | finance.yahoo.comPharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in AustraliaFebruary 21, 2024 | globenewswire.comPharmaTher's Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in AustraliaFebruary 12, 2024 | finanznachrichten.dePharmaTher Holdings Ltd.: PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for KetamineFebruary 12, 2024 | finance.yahoo.comPharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for KetamineJanuary 16, 2024 | benzinga.comPharmaTher Holdings Stock (OTC:PHRRF) Dividends: History, Yield and DatesJanuary 10, 2024 | finanznachrichten.dePharmaTher Holdings Ltd.: PharmaTher Provides Update for Expected FDA Approval of KetamineJanuary 10, 2024 | msn.comPharmaTher expects FDA to decide on ketamine approval by April 29January 10, 2024 | finance.yahoo.comPharmaTher Provides Update for Expected FDA Approval of KetamineDecember 23, 2023 | seekingalpha.comPHRRF PharmaTher Holdings Ltd.November 11, 2023 | morningstar.comPharmaTher Holdings Ltd PHRRFNovember 11, 2023 | investing.comPharmather Holdings Ltd (PHRM)September 27, 2023 | finanznachrichten.dePharmaTher Holdings Ltd.: PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX (Ketamine)September 27, 2023 | finance.yahoo.comPharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)September 17, 2023 | msn.comWith ecstasy a potential PTSD therapy, psychedelic treatments could take offSeptember 6, 2023 | benzinga.comPharmaTher Aims To Mitigate Ketamine Shortage With New FDA ApplicationSeptember 6, 2023 | finance.yahoo.comPharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDASee More Headlines Receive PHRRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PharmaTher and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTC SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTC:PHRRF CUSIPN/A CIKN/A Webwww.pharmather.com Phone888 846 3171FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Fabio Chianelli (Age 46)Founder, Chairman & CEO Comp: $233.78kMr. Carmelo Marrelli ACIS (Age 53)B.Comm., C.A., CGA, CPA, Chief Financial Officer Comp: $72.14kMr. Andrew Todd (Age 66)Corporate Secretary Key Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors PHRRF Stock Analysis - Frequently Asked Questions How have PHRRF shares performed in 2024? PharmaTher's stock was trading at $0.24 at the start of the year. Since then, PHRRF stock has decreased by 33.3% and is now trading at $0.16. View the best growth stocks for 2024 here. How do I buy shares of PharmaTher? Shares of PHRRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTC:PHRRF) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Presidential candidate you should REALLY be worried aboutStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressMost important medical advance in 100 yearsThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders Alliance Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaTher Holdings Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.